CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease

Completed

Conditions studied: Alzheimer's Disease

In brief

Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests. The goal of this project is to study how amyloid-beta (a protein thought to cause AD) is made, transported and cleared in the human body. Better understanding of these processes may lead to improved understanding of AD, earlier diagnosis and a way to evaluate treatment.

Key facts

Study ID

NCT02021682

Run by

Washington University School of Medicine

People needed

58

Starts

2013-12-01

Expected to finish

2017-07-01

Last updated by the study team

2017-12-05

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Member of the Memory and Aging Project at Washington University
• Clinical Dementia Rating (CDR) and PET/ PIB scores
• Age 60 or greater

You may not qualify if…

• Clotting disorder
• Active anticoagulation therapy
• Active infection
• Meningitis
• Recent syncope
• Currently on experimental treatment targeting Aβ or medications thought to influence Aβ production or clearance rates (benzodiazepines, muscarinic agents, or anti-epileptics)

Where it is running

• Washington University in St. Louis — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.